Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles

References

• Bale AS, Barone Jr S, Scott CS, Cooper GS. (2011). A review of potential neurotoxic mechanisms among three chlorinated organic solvents. Toxicol Appl Pharmacol 255:113–26
   PubMed Web of Science ®Google Scholar
• Carstens MG, De Jong PH, Van Nostrum CF, et al. (2008). The effect of core composition in biodegradable oligomeric micelles as taxane formulations. Eur J Pharm Biopharm 68:596–606
   PubMed Web of Science ®Google Scholar
• Cheon Lee S, Kim C, Chan Kwon I, et al. (2003). Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(epsilon-caprolactone) copolymer as a carrier for paclitaxel. J Control Release 89:437–46
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, et al. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–16
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Rivory LP. (1999). Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. (2014). A registry and results database of publicly and privately supported clinical studies of human participants conducted around the world [Online]. U.S. National Institutes of Health. Available: http://www.clinicaltrial.gov/ct2/show/NCT(0053)(1271)?term=abi-008&rank=1 [last accessed 20 Dec 2014]
   Google Scholar
• Davis ME, Chen ZG, Shin DM. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–82
   PubMed Web of Science ®Google Scholar
• De T, Veith J, Bernacki RJ, et al. (2005). Nab-028 a nanoparticle albumin-bound novel taxane, shows improved efficacy an lower toxicity over the tween formulation (Tween-028). Proc Am Assoc Cancer Res Annual Meeting 46:335
   Google Scholar
• de Oliveira R, Zhao P, Li N, et al. (2013). Synthesis and in vitro studies of gold nanoparticles loaded with docetaxel. Int J Pharm 454:703–11
   PubMed Web of Science ®Google Scholar
• Desai N. (2007). Nab technology: a drug delivery platform utilizing endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Deliv Rep Winter 2007/2008:37–41
   Google Scholar
• Desai N, Soon-Shiong P, Trieu V. (2010). Compositions and methods of delivery of pharmacological agents. US20100226996. 09 Sep 2010
   Google Scholar
• Desai N, Trieu V, Yang A, et al. (2006a). Enhanced efficacy and safety of nanoparticle albumin-bound nab-docetaxel versus taxotere. Proc Am Assoc Cancer Res Annual Meeting 47:1277–8
   Google Scholar
• Desai N, Trieu V, Yao Z, et al. (2006b). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–24
   PubMed Web of Science ®Google Scholar
• Ding D, Tang X, Cao X, et al. (2014). Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy. AAPS PharmSciTech 15:213–22
   PubMed Web of Science ®Google Scholar
• Drugs@FDA. (2014). FDA approved drug products [Online]. U.S. Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [last accessed 20 Dec 2014]
   Google Scholar
• Du W, Hong L, Yao T, et al. (2007). Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg Med Chem 15:6323–30
   PubMed Web of Science ®Google Scholar
• Duncan R. (2003). The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347–60
   PubMed Web of Science ®Google Scholar
• Elzoghby AO, Samy WM, Elgindy NA. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157:168–82
   PubMed Web of Science ®Google Scholar
• Ferrari M. (2005). Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–71
   PubMed Web of Science ®Google Scholar
• Fu Q, Sun J, Zhang W, et al. (2009). Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov 4:262–72
   PubMed Web of Science ®Google Scholar
• Gong G, Xu Y, Zhou Y, et al. (2012). Molecular switch for the assembly of lipophilic drug incorporated plasma protein nanoparticles and in vivo image. Biomacromolecules 13:23–8
   PubMed Web of Science ®Google Scholar
• Gong G, Zhi F, Wang K, et al. (2011). Fabrication of a nanocarrier system through self-assembly of plasma protein and its tumor targeting. Nanotechnology 22:295603
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. (2008). Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:876–85
   PubMed Web of Science ®Google Scholar
• Hu Y, Wu J, Ding D, et al. (2011). Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding. 17 Feb 2011. WO/2011/017,835
   Google Scholar
• Immordino ML, Brusa P, Arpicco S, et al. (2003). Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 91:417–29
   PubMed Web of Science ®Google Scholar
• Jiang S, Gong X, Zhao X, Zu Y. (2015). Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles. Drug Deliv 22:206–13
   PubMed Web of Science ®Google Scholar
• Konigsberg W. (1972). [13] Reduction of disulfide bonds in proteins with dithiothreitol. Methods Enzymol 25:185–8
   PubMedGoogle Scholar
• Kratz F. (2008). Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–83
   PubMed Web of Science ®Google Scholar
• Kutty RV, Feng SS. (2013). Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials 34:10160–71
   PubMed Web of Science ®Google Scholar
• Leonhard V, Alasino RV, Bianco ID, et al. (2012). Self-assembled micelles of monosialogangliosides as nanodelivery vehicles for taxanes. J Control Release 162:619–27
   PubMed Web of Science ®Google Scholar
• Liu Y, Li K, Pan J, et al. (2010). Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 31:330–8
   PubMed Web of Science ®Google Scholar
• Maham A, Tang Z, Wu H, et al. (2009). Protein-based nanomedicine platforms for drug delivery. Small 5:1706–21
   PubMed Web of Science ®Google Scholar
• Malam Y, Loizidou M, Seifalian AM. (2009). Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30:592–9
   PubMed Web of Science ®Google Scholar
• Mastropaolo D, Camerman A, Luo Y, et al. (1995). Crystal and molecular structure of paclitaxel (taxol). Proc Natl Acad Sci U S A 92:6920–4
   PubMed Web of Science ®Google Scholar
• Muthu MS, Kulkarni SA, Raju A, Feng SS. (2012). Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 33:3494–501
   PubMed Web of Science ®Google Scholar
• Nuijen B, Bouma M, Schellens JH, Beijnen JH. (2001). Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 19:143–53
   PubMed Web of Science ®Google Scholar
• Paal K, Shkarupin A. (2007). Paclitaxel binding to the fatty acid-induced conformation of human serum albumin – automated docking studies. Bioorg Med Chem 15:7568–75
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–60
   PubMed Web of Science ®Google Scholar
• Peng L, Liu R, Marik J, et al. (2006). Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2:381–9
   PubMed Web of Science ®Google Scholar
• Qiu Y, Gao Y, Hu K, Li F. (2008). Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J Control Release 129:144–50
   PubMed Web of Science ®Google Scholar
• Quaglia F, Ostacolo L, Mazzaglia A, et al. (2009). The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 30:374–82
   PubMed Web of Science ®Google Scholar
• Rihova B. (1996). Biocompatibility of biomaterials: hemocompatibility, immunocompatiblity and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv Drug Deliv Rev 21:157–76
   Web of Science ®Google Scholar
• Ringel I, Horwitz SB. (1991). Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83:288–91
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. (2014). Product information of Taxotere®. [Online]. Sanofi-Aventis U.S. LLC. Available at: http://products.sanofi.us/Taxotere/taxotere.html [last accessed 05 Oct 2014]
   Google Scholar
• Sugio S, Kashima A, Mochizuki S, et al. (1999). Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 12:439–46
   PubMedGoogle Scholar
• ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. (2003). Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42:665–85
   PubMed Web of Science ®Google Scholar
• Tong SW, Xiang B, Dong DW, Qi XR. (2012). Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles. Int J Pharm 434:413–19
   PubMed Web of Science ®Google Scholar
• Upadhyay KK, Bhatt AN, Castro E, et al. (2010). In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol Biosci 10:503–12
   PubMed Web of Science ®Google Scholar
• Venkatraman SS, Ma LL, Natarajan JV, Chattopadhyay S. (2010). Polymer- and liposome-based nanoparticles in targeted drug delivery. Front Biosci (Schol Ed) 2:801–14
   PubMedGoogle Scholar
• Wang J, Sui M, Fan W. (2010). Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab 11:129–41
   PubMed Web of Science ®Google Scholar
• Yang JT, Wu CS, Martinez HM. (1986). Calculation of protein conformation from circular dichroism. Methods Enzymol 130:208–69
   PubMed Web of Science ®Google Scholar